Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
02 June 2016Website:
http://clearsidebio.comNext earnings report:
13 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 11 min agoDividend
Analysts recommendations
Institutional Ownership
CLSD Latest News
Clearside Biomedical (CLSD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.15 per share a year ago.
ALPHARETTA, Ga., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that management will present a corporate update at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference which will be available on demand on Thursday, August 15, 2024, at 7:00 a.m. ET. Victor Chong, MD, MBA, Chief Medical Officer, will also participate in a panel discussion on the Evolving Therapeutic Landscape of AMD.
Clearside Biomedical (CLSD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clearside Biomedical, Inc. (NASDAQ:CLSD ) Suprachoroidal Space Drug Delivery Call July 24, 2024 8:00 AM ET Company Participants Jenny Kobin - Investor Relations George Lasezkay - President and Chief Executive Officer Glenn Yiu - Scientific Advisory Board Victor Chong - Chief Medical Officer David Brown - Director of Research, Retina Consultants Houston Conference Call Participants Annabel Samimy - Stifel Andreas Argyrides - Oppenheimer & Co. Serge Belanger - Needham & Company Yi Chen - H.C. Wainwright Operator Greetings, and welcome to the Clearside Biomedical KOL Webinar.
ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of industry-leading retinal physicians who provide medical and scientific expertise and input on the Company's research and development programs.
Oppenheimer initiated coverage on Clearside Biomedical Inc CLSD, a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal (SCS) space.
ALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company transforming the way treatments are delivered to the back of the eye using the suprachoroidal space (SCS®), announced today that it will release its financial results for the first quarter of 2024 on Thursday, May 9, 2024 after the markets close. A webcast and conference call will be held by management at 4:30 p.m. Eastern Time to discuss the results and provide an update on the company.
Clearside Biomedical, Inc. (CLSD) Q4 2023 Earnings Call Transcript
ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2023 financial results will be reported on Tuesday, March 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
What type of business is Clearside Biomedical?
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
What sector is Clearside Biomedical in?
Clearside Biomedical is in the Healthcare sector
What industry is Clearside Biomedical in?
Clearside Biomedical is in the Biotechnology industry
What country is Clearside Biomedical from?
Clearside Biomedical is headquartered in United States
When did Clearside Biomedical go public?
Clearside Biomedical initial public offering (IPO) was on 02 June 2016
What is Clearside Biomedical website?
https://clearsidebio.com
Is Clearside Biomedical in the S&P 500?
No, Clearside Biomedical is not included in the S&P 500 index
Is Clearside Biomedical in the NASDAQ 100?
No, Clearside Biomedical is not included in the NASDAQ 100 index
Is Clearside Biomedical in the Dow Jones?
No, Clearside Biomedical is not included in the Dow Jones index
When was Clearside Biomedical the previous earnings report?
No data
When does Clearside Biomedical earnings report?
The next expected earnings date for Clearside Biomedical is 13 November 2024